Vascular endothelial cadherin shedding is more severe in sepsis patients with severe acute kidney injury

• Published in: Critical care (London, England) Vol. 23; no. 1; p. 18
• Main Authors: Yu, Wen-Kuang, McNeil, J Brennan, Wickersham, Nancy E, Shaver, Ciara M, Bastarache, Julie A, Ware, Lorraine B
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 18.01.2019; BioMed Central; BMC
• Subjects: Acute kidney failure; Acute kidney injury; Acute Kidney Injury - etiology; Acute Kidney Injury - metabolism; Acute Kidney Injury - physiopathology; Adult; Adult respiratory distress syndrome; Aged; Analysis; Antigens, CD - analysis; Antigens, CD - blood; Antigens, CD - metabolism; APACHE; Atherosclerosis; Autoimmune diseases; Biomarkers - analysis; Biomarkers - blood; Cadherins; Cadherins - analysis; Cadherins - blood; Cadherins - metabolism; Cohort Studies; Complications and side effects; Endothelial injury; Endothelium; Female; Health aspects; Humans; Infection; Kidney diseases; Male; Middle Aged; Mortality; Organ Dysfunction Scores; Permeability; Prospective Studies; Renal replacement therapy; Respiratory distress syndrome; Respiratory insufficiency; Sepsis; Sepsis - blood; Sepsis - complications; Sepsis - physiopathology; Soluble vascular endothelial cadherin; Statistics, Nonparametric; China; Sepsis; Endothelial injury; Renal replacement therapy; Soluble vascular endothelial cadherin; Acute kidney injury
• ISSN: 1364-8535; 1466-609X; 1364-8535
• DOI: 10.1186/s13054-019-2315-y

Vascular endothelial cadherin (VE-cadherin) is a membrane protein that is the major component of adherens junctions between endothelial cells. It is crucial for regulating vascular integrity, endothelial permeability, and angiogenesis. During inflammatory processes, VE-cadherin is shed into circulation (sVE-cadherin). Plasma sVE-cadherin is elevated in sepsis, malignancy, autoimmune diseases, and coronary atherosclerosis. However, the relationship between specific organ failures, especially severe acute kidney injury (AKI) defined by requirement for renal replacement therapy (AKI-RRT), and plasma sVE-cadherin levels in severe sepsis has not been well studied. The present study is a prospective study of critically ill adults with sepsis and acute respiratory failure (age ≥ 18 years) enrolled in the Validating Acute Lung Injury markers for Diagnosis (VALID) study. Plasma sVE-cadherin was measured at study enrollment. Primary analysis focused on the association between sVE-cadherin levels and the development of AKI, AKI-RRT, other organ dysfunction as defined by Brussels organ failure scores, pulmonary versus non-pulmonary sepsis, acute respiratory distress syndrome (ARDS), and in-hospital mortality. Of 228 severe sepsis patients included, 80 (35%) developed AKI-RRT. Plasma sVE-cadherin levels at enrollment were significantly higher in patients with AKI-RRT compared with patients without AKI-RRT (p = 0.003). Plasma sVE-cadherin levels by quartile were significantly higher in severe sepsis patients with acute kidney injury stage 3 (p = 0.044) as defined by Kidney Disease Improving Global Outcomes (KDIGO) criteria. Patients with greater than 2 organ failures had higher plasma sVE-cadherin levels than patients with 2 or fewer organ failures (p < 0.001). In a multivariable analysis, plasma sVE-cadherin was independently associated with AKI-RRT (odds ratio 6.44 per log increase in plasma sVE-cadherin, 95% CI 1.126-36.847, p = 0.036). Plasma sVE-cadherin levels were significantly higher in patients with non-pulmonary sepsis compared to pulmonary sepsis (p < 0.001). Shedding of sVE-cadherin is associated with severe acute kidney injury and with more severe organ dysfunction in patients with sepsis, suggesting that breakdown of endothelial adherens junctions may contribute to the pathogenesis of organ dysfunction in sepsis. Further studies of sVE-cadherin as a biomarker of disease severity in clinical sepsis are needed to better elucidate the role of VE-cadherin shedding in sepsis-induced severe organ dysfunction.